Clinical Trial Update: Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery [NA]

View source ↗

Summary

Clinical trial evaluating erythropoietin for myocardial ischemia-reperfusion injury during coronary artery bypass grafting has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemia-reperfusion Injury
• Myocardial Ischemia

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Shahid Beheshti University of Medical Sciences | Conditions: Myocardial Ischemic Reperfusion Injury | NA | Status: COMPLETED